 Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on AUTO3, the companys CAR T cell therapy being investigated in the ALEXANDER study, a Phase 12 study in relapsedrefractory diffuse large B cell lymphoma DLBCL, during the Annual Society of Clinical Oncology 2020 ASCO20 Virtual Scientific Program beginning May 29. Data from the ALEXANDER trial of AUTO3, a CD19CD22 dual-targeting CAR T product candidate in DLBCL have shown a complete response rate of 63 at the recommended Phase 2 dose range with an excellent safety profile, said Dr. Aravind Ramakrishnan, Medical Director, Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center. 